SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

VARANI, Katia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 50.084
AS - Asia 26.428
EU - Europa 16.770
SA - Sud America 4.102
Continente sconosciuto - Info sul continente non disponibili 766
AF - Africa 552
OC - Oceania 47
AN - Antartide 1
Totale 98.750
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 48.849
SG - Singapore 9.367
CN - Cina 6.791
BR - Brasile 3.133
VN - Vietnam 3.026
DE - Germania 2.993
FI - Finlandia 2.928
IT - Italia 2.706
UA - Ucraina 2.386
HK - Hong Kong 2.169
TR - Turchia 1.932
GB - Regno Unito 1.497
FR - Francia 949
SE - Svezia 944
RU - Federazione Russa 754
BD - Bangladesh 637
JP - Giappone 633
CA - Canada 614
IN - India 537
PL - Polonia 533
MX - Messico 385
AR - Argentina 345
ID - Indonesia 252
NL - Olanda 248
ZA - Sudafrica 203
IQ - Iraq 187
ES - Italia 163
EC - Ecuador 156
CO - Colombia 139
BE - Belgio 128
PK - Pakistan 112
VE - Venezuela 100
LT - Lituania 98
UZ - Uzbekistan 90
MA - Marocco 85
SA - Arabia Saudita 85
AT - Austria 78
MY - Malesia 74
CZ - Repubblica Ceca 73
CL - Cile 72
PH - Filippine 72
AE - Emirati Arabi Uniti 67
TN - Tunisia 61
KE - Kenya 54
PY - Paraguay 54
JM - Giamaica 52
JO - Giordania 43
CR - Costa Rica 41
AU - Australia 35
UY - Uruguay 34
IL - Israele 33
CH - Svizzera 32
EG - Egitto 32
KR - Corea 32
PE - Perù 32
NP - Nepal 31
IE - Irlanda 30
BO - Bolivia 29
DZ - Algeria 29
HN - Honduras 27
IR - Iran 26
RO - Romania 25
AL - Albania 24
TT - Trinidad e Tobago 23
TW - Taiwan 23
AZ - Azerbaigian 22
PT - Portogallo 20
KZ - Kazakistan 19
EU - Europa 18
TH - Thailandia 18
ET - Etiopia 17
LB - Libano 16
BG - Bulgaria 15
KG - Kirghizistan 15
OM - Oman 15
PS - Palestinian Territory 15
BH - Bahrain 14
DO - Repubblica Dominicana 14
GT - Guatemala 14
HU - Ungheria 14
RS - Serbia 14
SY - Repubblica araba siriana 14
LV - Lettonia 13
HR - Croazia 12
MD - Moldavia 12
NO - Norvegia 12
SV - El Salvador 12
AM - Armenia 11
BA - Bosnia-Erzegovina 11
BY - Bielorussia 11
GR - Grecia 11
CI - Costa d'Avorio 10
NI - Nicaragua 10
SN - Senegal 10
NZ - Nuova Zelanda 9
PA - Panama 9
AO - Angola 8
CG - Congo 8
PR - Porto Rico 8
QA - Qatar 8
Totale 97.851
Salva come PNG Salva come JPEG
Città #
Singapore 6.048
Ashburn 5.041
Woodbridge 3.958
San Jose 3.482
Fairfield 3.397
Jacksonville 2.612
Chandler 2.494
Houston 2.449
Helsinki 2.234
Ann Arbor 2.134
Hong Kong 2.125
Beijing 2.074
Santa Clara 2.070
Dallas 1.558
Council Bluffs 1.439
Wilmington 1.428
Seattle 1.364
Cambridge 1.110
Ho Chi Minh City 986
Izmir 894
Los Angeles 866
Nanjing 785
Hanoi 701
New York 651
Tokyo 604
Princeton 586
Ferrara 527
Munich 527
Lauterbourg 485
Warsaw 484
Boardman 478
Milan 421
São Paulo 323
Shanghai 321
San Diego 311
Nanchang 252
Orem 247
Shenyang 236
Mexico City 233
London 203
Buffalo 199
Chicago 195
Tianjin 190
Turku 188
Toronto 187
Dearborn 179
Hefei 174
Bremen 167
Montreal 166
Frankfurt am Main 163
Changsha 158
Chennai 156
The Dalles 155
Falkenstein 153
Brooklyn 149
Hebei 147
Jakarta 144
Da Nang 142
Addison 140
Jiaxing 137
Denver 136
Phoenix 135
Haiphong 128
Atlanta 124
San Francisco 124
Brussels 122
Rome 112
Johannesburg 108
Manchester 104
Moscow 99
San Mateo 99
Stockholm 97
Jinan 95
Rio de Janeiro 95
Zhengzhou 93
Falls Church 90
Bologna 88
Norwalk 85
Amsterdam 83
Boston 82
Kunming 82
Dong Ket 81
Tashkent 80
Poplar 78
Baghdad 76
Guangzhou 76
Mountain View 70
Philadelphia 70
Ankara 64
Columbus 62
Biên Hòa 61
Auburn Hills 59
Belo Horizonte 59
Düsseldorf 58
Orange 58
Washington 58
Charlotte 57
Hải Dương 56
Ningbo 55
Mumbai 53
Totale 64.839
Salva come PNG Salva come JPEG
Nome #
1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists 3.124
Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on “tetrad”, sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies 428
Pharmacology of Adenosine Receptors: The State of the Art 423
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors 388
Dose and time effects of caffeine intake on human platelet adenosine A2A receptors: functional and biochemical aspects 365
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 331
Caffeine alters A(2A) adenosine receptors and their function in human platelets 331
A glance at adenosine receptors: Novel target for antitumor therapy 322
Synthesis and Structure Activity Relationship Investigation of Triazolo[1,5-a]pyrimidines as CB2 Cannabinoid Receptor Inverse Agonists 317
Alterazioni dei recettori alfa(2) adrenergici delle piastrine umane nell'ipertensione essenziale 314
Psychostimulant effect of the synthetic cannabinoid JWH-018 and AKB48. Behavioural, neurochemical and Dopamine transporter scan imaging studies in mice 310
Positive allosteric modulation of A1 adenosine receptors as a novel and promising therapeutic strategy for anxiety 306
Inhibition of A2A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455 300
A(2B) adenosine receptors stimulate IL-6 production in primary murine microglia through p38 MAPK kinase pathway 295
The A3 adenosine receptor: history and perspectives 294
Effect of JWH-250, JWH-073 and their interaction on “tetrad”, sensorimotor, neurological and neurochemical responses in mice 292
Design, synthesis, and biological evaluation of novel 2-((2-(4-(substituted)phenylpiperazin-1-yl)ethyl)amino)-5'-N-ethylcarboxamidoadenosines as potent and selective agonists of the A2A adenosine receptor 286
Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice 285
2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation 284
Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects? 280
Recettori e trasduzione del segnale 278
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice 276
Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease 273
Pulsed Electromagnetic Field Exposure Reduces Hypoxia and Inflammation Damage in Neuron-Like and Microglial Cells 273
Characterization of adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes exposed to low frequency low energy pulsed electromagnetic fields 269
Pulsed Electromagnetic Fields: A Novel Attractive Therapeutic Opportunity for Neuroprotection After Acute Cerebral Ischemia 269
A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release 268
Repeated dosing with NCX1404, a nitric oxide-donating pregabalin, re-establishes normal nociceptive responses in mice with streptozotocin-induced painful diabetic neuropathy 266
Recettori e trasduzione del segnale 265
Adenosine receptors and human melanoma 264
[H-3]MRE 3008F20: A novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors 264
A1 and A3 adenosine receptors inhibit LPS-induced hypoxia-inducible factor-1 accumulation in murine astrocytes 263
7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as Selective CB2 Cannabinoid Receptor Ligands: Structural Investigations around a Novel Class of Full Agonists 262
Adenosine analogs and electromagnetic fields inhibit prostaglandin E2 release in bovine synovial fibroblasts 261
[H-3]-MRE 2029-F20, a selective antagonist radioligand for the human A(2B) adenosine receptors 260
The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and selectivity profiles 257
N-6-[(Hetero)aryl/(cyclo)alkyl-carbamoyi-methoxy-phenyl]-(2chloro)-5 '-N-ethylearboxamido-adenosines: The first example of adenosine-related structures with potent agonist activity at the human A(2B) adenosine receptor 254
A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats 254
6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors 251
Effects of two-carbon bridge region methoxylation of benztropine: discovery of novel chiral ligands for the dopamine transporter 251
Effect of low frequency electromagnetic fields on A2A adenosine receptors in human neutrophils. 249
“Bridging the Gap” Everything that Could Have Been Avoided If We Had Applied Gender Medicine, Pharmacogenetics and Personalized Medicine in the Gender-Omics and Sex-Omics Era 249
New 2-heterocyclyl-imidazo[2,1- i ]purin-5-one derivatives as potent and selective human A 3 adenosine receptor antagonists 249
Role and function of A2A and A3 adenosine receptors in patients with ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis 247
Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes. 247
A(2A) adenosine receptors are up-regulated in lymphocytes from amyotrophic lateral sclerosis patients 247
History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents 246
Pharmaco-toxicological effects of the novel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In vitro and in vivo studies 245
Ala scan analogues of HOE 140. Synthesis and biological activities 244
Comparison of prazosin, terazosin and tamsulosin: Functional and binding studies in isolated prostatic and vascular human tissues 244
New heterocyclic ligands for the adenosine receptors P1 and for the ATP receptors P2. 243
Alteration of A3 adenosine receptors in human neutrophils and low frequency electromagnetic fields 242
Adenosine A1 receptors in the rat brain in the kindling model of epilepsy 242
Multiple sclerosis lymphocytes upregulate A(2A) adenosine receptors that are antiinflammatory when stimulated 241
5-heteroarylcarbamoylamino-pyrazolo-triazolo pyrimidines as hA3 adenosine receptor antagonists. 240
HIF-1 neuroprotection through erythropoietin increase in hypoxia: a role for A1 adenosine receptors 238
Cannabinoid CB2 receptor attenuates morphine-induced inflammatory responses in activated microglial cells 237
Biological activity of for-Met-Leu-Phe-OMe analogs: relevant substitutions specifically trigger killing mechanisms in human neutrophils 237
Adenosine modulates vascular endothelial growth factor expression via hypoxiainducible factor-1 in human glioblastoma cells. 236
One-pot reaction to obtain N,N'-disubstituted guanidines of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold as human A3 adenosine receptor antagonists 236
Adenosine signaling contributes to ethanol-induced fatty liver in mice 234
The activation of μ-opioid receptor potentiates LPS-induced NF-kB promoting an inflammatory phenotype in microglia 234
A3 Receptors are Overexpressed in Pleura from Mesothelioma Patients and Reduce Cell Growth via Akt/NF-kB Pathway. 232
Adenosine receptor targeting in health and disease 230
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor 230
Alteration of adenosine receptore in patients with chronic obstructive pulmonary disease 228
Current status of A1 adenosine receptor allosteric enhancers 227
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A2A Adenosine Receptor Inverse Agonists with Antinociceptive Activity 227
ALTERATION OF ADENOSINE RECEPTORS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 226
A3 adenosine receptors are overexpressed in pleura from patients with mesothelioma and reduce malignant mesothelioma cell growth 226
[3H]-MRE 2029-F20, a novel selective antagonist radioligand, for the pharmacological and biochemical characterization of A2B receptors. 226
van't Hoff Based Thermodynamics 226
Binding thermodynamics and intrinsic activity of adenosine A1 receptor ligands 225
A3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study 225
Biological effects of novel 2-amino-3-naphthoylthiophenes as allosteric enhancers of the A1 adenosine receptors 225
Further studies on nociceptin-related peptides: Discovery of a new chemical template with antagonist activity on the nociceptin receptor 224
M3 muscarinic receptors in peripheral lung parenchima of patients with chronic obstructive pulmonary disease. 223
The Anti-Tumor Effect of A(3) Adenosine Receptors Is Potentiated by Pulsed Electromagnetic Fields in Cultured Neural Cancer Cells 223
7-substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A(2A) adenosine receptor antagonists: A study on the importance of modifications at the side chain on the activity and solubility 223
Effects of doxazosin and propranolol on A2A adenosine receptors in essential hypertension 222
A2A adenosine receptor upregulation correlates with disease activity in patients with systemic lupus erythematosus 222
Targeting A3 and A2A adenosine receptors in the fight against cancer 222
Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells 220
Asymmetrical nitrido tc-99m heterocomplexes as potential imaging agents for benzodiazepine receptors 220
7-substituted-5-amino-2-(furyl)-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: importance of modifications at the side chain on the activity and solubility. 220
Structure-activity relationship studies of a new series of imidazo[2,1-f] purinones as potent and selective A3 adenosine receptor antagonists 220
P2X1 and P2X3 Purinergic Receptors Differentially Modulate the Inflammatory Response in Human Osteoarthritic Synovial Fibroblasts 220
3H SCH 58261 labelling of functional A2A adenosine receptors in human neutrophil membranes 220
Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors 220
Adenosine Receptors as a Biological Pathway for the Anti-Inflammatory and Beneficial Effects of Low Frequency Low Energy Pulsed Electromagnetic Fields 220
Adenosine modulates HIF-1, VEGF, IL-8 and foam cells formation in a human model of hypoxic foam cells 219
Synthesis and pharmacology of 6-substituted benztropines: Discovery of novel dopamine uptake inhibitors possessing low binding affinity to the dopamine transporter 219
Pathological overproduction: the bad side of adenosine 219
Receptor binding at two different temperatures to discriminate agonist and antagonist behaviour of adenosine A1 receptor ligands in rat brain 218
Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists 218
[3H]MRE2029F20 a new selective antagonist radioligand for the human A2B adenosine receptors. 218
THERMODYNAMICS OF A2B ADENOSINE RECEPTOR BINDING DISCRIMINATES AGONISTIC FROM ANTAGONISTIC BEHAVIOUR 218
Microwave-assisted synthesis of thieno[2,3-c]pyridine derivatives as a new series of allosteric enhancers at the adenosine A(1) receptor 218
4-Amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies 217
Agonists and antagonists: Molecular mechanisms and therapeutic applications 217
Totale 28.333
Salva come PNG Salva come JPEG
Categoria #
all - tutte 419.064
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 9.246
Totale 428.310
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.457 0 0 340 225 245 210 231 269 190 431 728 1.588
2022/20235.722 591 430 176 792 952 820 268 458 698 46 296 195
2023/20242.844 288 377 142 83 314 342 136 208 57 72 77 748
2024/202512.257 311 354 944 615 1.429 1.132 460 739 1.725 1.388 1.708 1.452
2025/202637.522 3.428 1.621 3.577 4.452 4.958 2.335 3.971 1.786 5.237 3.965 1.419 773
2026/20274.669 1.251 2.244 1.174 0 0 0 0 0 0 0 0 0
Totale 98.750